Genelux Corp. GNLX 深 沪
等待开盘 11-04 09:30:00 美东时间
8.24
+0.160
+1.98%
华盛通- 最 高8.461
- 今 开8.12
- 成交量 24.23万股
- 最 低 7.764
- 昨 收 8.08
- 总市值 3.11亿
- 52周最高 8.461
- 市盈率 静 --
- 换手率 0.64%
- 52周最低 1.9875
- 委 比 33.33%
- 总股本 3777.34万
- 历史最高 40.98
- 量 比 1.02
- 振 幅 8.63%
- 历史最低 1.60
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Lake Street Initiates Coverage On Genelux with Buy Rating, Announces Price Target of $16
Lake Street analyst Chad Messer initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Price Target of $16.
10-21 22:54
Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
<p>Genelux Corporation announced that its President, CEO, and Chairman Thomas Zindrick, along with CFO Matt Pulisic, will participate in a fireside chat at H.C. Wainwright & Co's Annual Global Investment Conference on September 9, 2025. The session, moderated by biotech analyst Emily Bodnar, will start at 2:30 p.m. ET. Interested parties can register and view the session via the provided link, with an archived replay available for 90 days post-ev...
09-02 20:01
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
Genelux Corporation reported second-quarter 2025 financial results and updated its business progress. The company continues advancing its Olvi-Vec therapy, with promising clinical trial results expected in the coming year, particularly in platinum-resistant ovarian and lung cancers. Recent leadership additions, including Eric Groen, strengthen operational capabilities. The company concluded Phase 3 trial alignment with the FDA and anticipates key...
08-07 20:20
美股大行评级 | 潜在涨幅23.77%！美国运通获德银升目标价至375美元，维持"买入"评级
今日重点评级关注：德银：维持美国运通"买入"评级，目标价从371美元升至375美元；巴克莱：维持Gaming and Leisure Props"标配"评级，目标价从54美元升至55美元
07-22 09:35
LUCID CAPITAL MARKETS Initiates Coverage On Genelux with Buy Rating, Announces Price Target of $10
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Genelux (NASDAQ:GNLX) with a Buy rating and announces Price Target of $10.
07-22 01:35
Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
<p>Genelux Corporation has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer, and Head of Business Development. Groen brings over two decades of experience in life sciences, including roles at Rani Therapeutics and Amgen, where he was involved in major transactions like Amgen’s acquisition of Onyx Pharmaceuticals. His expertise in legal, corporate law, mergers and acquisitions, licensing, compliance, and busin...
07-07 11:00
Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $23
Benchmark analyst Bruce Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $25 to $23.
05-08 22:04
Genelux GAAP EPS of -$0.21
Genelux press release (NASDAQ:GNLX): Q1 GAAP EPS of -$0.21. Cash, cash equivalents and short-term investments were $35.1 million as of March 31, 2025. More on Genelux Seeking Alpha’s Quant Rating on ...
05-07 21:53
Benchmark Co. Remains a Buy on Genelux Corp. (GNLX)
In a report released today, Bruce Jackson from Benchmark Co. maintained a Buy r...
04-08 19:35
